Endogenous sex steroids in premenopausal women and risk of breast cancer: The ORDET cohort

Breast Cancer Research

Volumn 15, Issue 3, 2013, Pages

  Schernhammer, Eva S ^a,b,c   Sperati, Francesca ^d   Razavi, Pedram ^e   Agnoli, Claudia ^f   Sieri, Sabina ^f   Berrino, Franco ^f   Krogh, Vittorio ^f   Abbagnato, Carlo Alberto ^g   Grioni, Sara ^f   Blandino, Giovanni ^d,h   Schunemann, Holger J ^h   Muti, Paola ^b,h  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c Kundratstrasse ^*  (Austria)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g Centro Medico Diagnostico Emilia   (Italy)

^h MCMASTER UNIVERSITY   (Canada)

Author keywords

androgens; breast cancer; estrogens; premenopausal; sex steroids

Indexed keywords

ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; PROGESTERONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; PREMENOPAUSE; PROGESTERONE BLOOD LEVEL; PROSPECTIVE STUDY; TESTOSTERONE BLOOD LEVEL; BLOOD; BREAST TUMOR; MIDDLE AGED; PATHOLOGY; RISK FACTOR;

ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; PREMENOPAUSE; PROGESTERONE; PROSPECTIVE STUDIES; RISK FACTORS; TESTOSTERONE;

EID: 84879044586     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3438     Document Type: Article

References (24)

1. Hankinson SE, Eliassen AH. Circulating sex steroids and breast cancer risk in premenopausal women. Horm Cancer 2010, 1:2-10. 10.1007/s12672-009-0003-0, 3253362, 21761346.
2. Folkerd EJ, Dowsett M. Influence of sex hormones on cancer progression. J Clin Oncol 2010, 28:4038-4044. 10.1200/JCO.2009.27.4290, 20644089.
3. Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PH, Biessy C, Dossus L, Lukanova A, Bingham S, Khaw KT, Allen NE, Bueno-de-Mesquita HB, van Gils CH, Grobbee D, Boeing H, Lahmann PH, Nagel G, Chang-Claude J, Clavel-Chapelon F, Fournier A, Thiebaut A, Gonzalez CA, Quiros JR, Tormo MJ, Ardanaz E, Amiano P, Krogh V, Palli D, Panico S, Tumino R, Vineis P, Trichopoulou A, Kalapothaki V, Trichopoulos D, Ferrari P, Norat T, Saracci R, Riboli E. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European Prospective Investigation into Cancer and Nutrition. Endocr Relat Cancer 2005, 12:1071-1082. 10.1677/erc.1.01038, 16322344.
4. Kaaks R, Berrino F, Key T, Rinaldi S, Dossus L, Biessy C, Secreto G, Amiano P, Bingham S, Boeing H, Bueno de Mesquita HB, Chang-Claude J, Clavel-Chapelon F, Fournier A, van Gils CH, Gonzalez CA, Gurrea AB, Critselis E, Khaw KT, Krogh V, Lahmann PH, Nagel G, Olsen A, Onland-Moret NC, Overvad K, Palli D, Panico S, Peeters P, Quiros JR, Roddam A, Thiebaut A, Tjønneland A, Chirlaque MD, Trichopoulou A, Trichopoulos D, Tumino R, Vineis P, Norat T, Ferrari P, Slimani N, Riboli E. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2005, 97:755-765. 10.1093/jnci/dji132, 15900045.
5. Helzlsouer KJ, Alberg AJ, Bush TL, Longcope C, Gordon GB, Comstock GW. A prospective study of endogenous hormones and breast cancer. Cancer Detect Prev 1994, 18:79-85.
6. Wysowski DK, Comstock GW, Helsing KJ, Lau HL. Sex hormone levels in serum in relation to the development of breast cancer. Am J Epidemiol 1987, 125:791-799.
7. Helzlsouer KJ, Gordon GB, Alberg AJ, Bush TL, Comstock GW. Relationship of prediagnostic serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing premenopausal breast cancer. Cancer Res 1992, 52:1-4.
8. Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE. A prospective study of estradiol and breast cancer in Japanese women. Cancer Epidemiol Biomarkers Prev 2000, 9:575-579.
9. Thomas HV, Key TJ, Allen DS, Moore JW, Dowsett M, Fentiman IS, Wang DY. A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey. Br J Cancer 1997, 76:401-405. 10.1038/bjc.1997.398, 2224063, 9252211.
10. Rosenberg CR, Pasternack BS, Shore RE, Koenig KL, Toniolo PG. Premenopausal estradiol levels and the risk of breast cancer: a new method of controlling for day of the menstrual cycle. Am J Epidemiol 1994, 140:518-525.
11. Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, Hankinson SE. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 2006, 98:1406-1415. 10.1093/jnci/djj376, 17018787.
12. Micheli A, Muti P, Secreto G, Krogh V, Meneghini E, Venturelli E, Sieri S, Pala V, Berrino F. Endogenous sex hormones and subsequent breast cancer in premenopausal women. Int J Cancer 2004, 112:312-318. 10.1002/ijc.20403, 15352045.
13. Muti P, Bradlow HL, Micheli A, Krogh V, Freudenheim JL, Schunemann HJ, Stanulla M, Yang J, Sepkovic DW, Trevisan M, Berrino F. Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology 2000, 11:635-640. 10.1097/00001648-200011000-00004, 11055622.
14. Meilahn EN, De Stavola B, Allen DS, Fentiman I, Bradlow HL, Sepkovic DW, Kuller LH. Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. Br J Cancer 1998, 78:1250-1255. 10.1038/bjc.1998.663, 2063014, 9820189.
15. Page JH, Colditz GA, Rifai N, Barbieri RL, Willett WC, Hankinson SE. Plasma adrenal androgens and risk of breast cancer in premenopausal women. Cancer Epidemiol Biomarkers Prev 2004, 13:1032-1036.
16. Tworoger SS, Missmer SA, Eliassen AH, Spiegelman D, Folkerd E, Dowsett M, Barbieri RL, Hankinson SE. The association of plasma DHEA and DHEA sulfate with breast cancer risk in predominantly premenopausal women. Cancer Epidemiol Biomarkers Prev 2006, 15:967-971. 10.1158/1055-9965.EPI-05-0976, 16702378.
17. Muti P, Stanulla M, Micheli A, Krogh V, Freudenheim JL, Yang J, Schunemann HJ, Trevisan M, Berrino F. Markers of insulin resistance and sex steroid hormone activity in relation to breast cancer risk: a prospective analysis of abdominal adiposity, sebum production, and hirsutism (Italy). Cancer Causes Control 2000, 11:721-730. 10.1023/A:1008966623901, 11065009.
18. Schernhammer ES, Berrino F, Krogh V, Secreto G, Micheli A, Venturelli E, Grioni S, Sempos CT, Cavalleri A, Schunemann HJ, Strano S, Muti P. Urinary 6-sulphatoxymelatonin levels and risk of breast cancer in premenopausal women: the ORDET cohort. Cancer Epidemiol Biomarkers Prev 2010, 19:729-737. 10.1158/1055-9965.EPI-09-1229, 2837369, 20200429.
19. Sieri S, Muti P, Claudia A, Berrino F, Pala V, Grioni S, Abagnato CA, Blandino G, Contiero P, Schunemann HJ, Krogh V. Prospective study on the role of glucose metabolism in breast cancer occurrence. Int J Cancer 2011, 130:921-929.
20. Berrino F, Muti P, Micheli A, Bolelli G, Krogh V, Sciajno R, Pisani P, Panico S, Secreto G. Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst 1996, 88:291-296. 10.1093/jnci/88.5.291, 8614008.
21. Berrino F, Pisani P, Muti P. Prospective study of hormones and diet in the aetiology of breast cancer. Diet, Hormones, and Cancer: Methodological Issues for Prospective Studies. Volume IARC Technical Report Number 4 1988, 34-38. Lyons: IARC, Riboli E, Saracci R.
22. Parkin DM, Whelan S, Ferlay J. Cancer incidence in five continents, vol. VII. IARC Scientific Publications Number 143 1997, Lyons: IARC.
23. Waterhouse J, Muir C, Shanmugaratnam K. IARC Scientific Publications. 1982, Lyons: IARC.
24. Missmer SA, Spiegelman D, Bertone-Johnson ER, Barbieri RL, Pollak MN, Hankinson SE. Reproducibility of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2- to 3-year period. Cancer Epidemiol Biomarkers Prev 2006, 15:972-978. 10.1158/1055-9965.EPI-05-0848, 16702379.